文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

阿奇霉素联合或不联合头孢克肟治疗南亚单纯性伤寒:ACT-South Asia 试验

Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.
PubMed 文献 · Lancet Infect Dis · 2026-08-20

在尼泊尔、孟加拉国和巴基斯坦开展的随机双盲安慰剂对照4期试验,纳入1847例临床疑似或血培养确诊的单纯性伤寒患者,比较阿奇霉素联合头孢克肟与阿奇霉素单药治疗。

要点

  • 支持WHO推荐阿奇霉素单药治疗单纯性伤寒,避免不必要联合用药。

核心结论

  • 研究支持WHO关于口服阿奇霉素单药治疗临床疑似或培养确诊单纯性伤寒的推荐。
  • 联合头孢克肟未降低治疗失败率,不支持加用头孢克肟。

研究设计与样本

  • 双盲、平行组、随机、安慰剂对照4期试验,在尼泊尔、孟加拉国和巴基斯坦开展。
  • 纳入2-65岁急性不明原因发热3-14天、C反应蛋白≥10 mg/L且登革热、恙虫病、疟疾和COVID-19检测阴性的患者。
  • 按1:1随机接受口服阿奇霉素(20 mg/kg,最大1 g,每日一次)联合头孢克肟(10 mg/kg,最大400 mg,每日两次)或阿奇霉素联合安慰剂,疗程7天。
  • 主要结局为复合治疗失败指标,在改良意向治疗人群中分析(1831例,其中350例血培养确诊)。

主要发现

  • 不良事件发生率两组均为16%(联合组142/918,单药组144/917),需住院的严重不良事件分别为21例(2%)和17例(2%)。

关键数值与推荐

  • WHO推荐口服阿奇霉素单药治疗单纯性伤寒。
  • 原文提及阿奇霉素和头孢克肟的失败率均有报告在10%或以上。
  • 主要结局治疗失败复合指标包括退热时间≥7天、第7天微生物学失败、需挽救治疗或28天内伤寒并发症或复发。

临床怎么用

  • 对临床疑似或培养确诊的单纯性伤寒,可遵循WHO推荐使用阿奇霉素单药治疗。
  • 无需常规加用头孢克肟,有助于抗菌药物合理使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: WHO recommends azithromycin for uncomplicated typhoid fever treatment. Cefixime is also commonly used, but both drugs have reported failure rates of 10% or more. We hypothesised that combining azithromycin's intracellular activity with the extracellular activity of cefixime could overcome each drugs' pharmacokinetic gaps and enhance tissue sterilisation. The study objective was to determine if a combination of azithromycin and cefixime would reduce treatment failure rates compared with azithromycin alone. METHODS: We did a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial in adults and children in Nepal, Bangladesh, and Pakistan with blood culture-confirmed or clinically suspected uncomplicated typhoid fever. Participants aged 2-65 years attending emergency and outpatient clinics with acute undifferentiated febrile illness lasting 3-14 days, C-reactive protein at least 10 mg/L, and negative tests for dengue, scrub typhus, malaria, and COVID-19, were randomly assigned 1:1 to receive oral azithromycin (20 mg/kg [maximum 1 g] once daily) and cefixime (10 mg/kg [maximum 400mg] twice daily) or oral azithromycin and placebo for 7 days. We used computer-generated block randomisation with blocks of 4 and 6, stratified by site and age; treatment allocation was concealed from all study personnel and participants throughout the study period. The primary outcome was a composite measure of treatment failure (fever clearance time ≥7 days, microbiological failure at day 7, need for rescue treatment, or typhoid fever complication or relapse within 28 days), which was analysed in the modified intention-to-treat population, defined as all randomly assigned participants who received at least one dose of study drug and did not test positive for COVID-19 by PCR at baseline. This trial is registered with ClinicalTrials.gov, NCT04349826, and has completed enrolment. FINDINGS: Between May 9, 2021, and Sept 30, 2025, we screened 46 947 individuals for eligibility, and 1847 were randomly assigned (926 to azithromycin-cefixime and 921 to azithromycin-placebo). 1831 eligible participants (350 with blood culture-confirmed typhoid) were included in the modified intention-to-treat population; 915 were assigned to azithromycin-cefixime and 916 to azithromycin-placebo. 44 (5·1%) participants had treatment failure in each group (absolute risk difference -0·00 percentage points, 95% CI -2·08 to 2·08; p=1·00). 19 (11·2%) of 179 culture-confirmed participants had treatment failure in the azithromycin-cefixime group versus 26 (16·0%) of 171 in the azithromycin-placebo group (absolute risk difference 4·48 percentage points, 95% CI -2·52 to 12·21; p=0·20). Adverse events occurred in 142 (16%) of 918 participants in the azithromycin-cefixime group and 144 (16%) of 917 in the azithromycin-placebo group. Serious adverse events requiring hospitalisation occurred in 21 participants (2%) and 17 participants (2%), respectively. INTERPRETATION: This study supports the WHO recommendation of oral azithromycin alone for treatment of clinically suspected or culture-confirmed uncomplicated typhoid fever,providing no evidence to support addition of cefixime, which has important implications for antimicrobial stewardship. FUNDING: The Department of Health and Social Care, the Foreign, Commonwealth & Development Office, the Medical Research Council, and Wellcome Trust.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Basnyat B, Adhikari S, Shrestha P, et al. Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial. Lancet Infect Dis. 2026. PMID: 42624818. doi:10.1016/S1473-3099(26)00358-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。